JC | Jotup

Evolution Credit Partners Welcomes JC Barone as Managing Director

Retrieved on:

Thursday, April 4, 2024

JPMorgan Chase, Insurance, JC, Chase Bank, Financial services

BOSTON and NEW YORK, April 4, 2024 /PRNewswire/ -- Evolution Credit Partners Management ("Evolution" or the "Firm"), an alternative credit firm with approximately $3 billion in assets under management, today announced John-Carl ("J.C.") Barone will be joining the Firm as a Managing Director.

Key Points:

BOSTON and NEW YORK, April 4, 2024 /PRNewswire/ -- Evolution Credit Partners Management ("Evolution" or the "Firm"), an alternative credit firm with approximately $3 billion in assets under management, today announced John-Carl ("J.C.") Barone will be joining the Firm as a Managing Director.
Mr. Barone brings a two-decade track record in the capital markets, focused on working capital finance, including trade finance and accounts receivable capital solutions for corporates.
Mr. Barone's hire will further Evolution's growing working capital finance business and its complementary leveraged finance business.
Most recently, Mr. Barone was with JP Morgan Chase Bank, where he served as Executive Director, Head of Alternative Credit Origination & Sales and oversaw the Global Alternative Credit Franchise, assessing client needs and establishing capital solutions.

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on:

Tuesday, March 5, 2024

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points:

These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
“The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

North River Leerink’s Successful 100 Chestnut Street Development Continues Somerville’s Growth as a Leading Life Science and Innovation Hub

Retrieved on:

Thursday, February 29, 2024

At the heart of this transformation stands 100 Chestnut, a purpose-built 200,000 sq.

Key Points:

At the heart of this transformation stands 100 Chestnut, a purpose-built 200,000 sq.
ft. Life Science building that is 90% leased, reflecting NRL's passion and focus on developing world-class buildings that enable innovation and support the creation of sustainable and vibrant communities.
Our goal is to contribute towards the development of a rich, vibrant and diverse district focused on fostering Art and enabling innovation in the Life Science/Biotech industry,” said Jeff Leerink, Managing Partner at NRL.
And most recently, ADA Forsyth, a leading institute dedicated to improving oral and overall health through innovative research and community outreach, has leased 76,000 sq.

Atlantix Partners Welcomes JC Jones Into Its Family of Brands

Retrieved on:

Tuesday, January 23, 2024

Other Professional Services, Accounting, Professional Services, Finance, J.C. Jones, JC, Partner, Information technology, Mail order

Atlantix Partners is pleased to announce JC Jones Advisory Services (“JC Jones”), a leading advisory firm headquartered in Rochester, New York, has joined the Atlantix Partners family of companies.

Key Points:

Atlantix Partners is pleased to announce JC Jones Advisory Services (“JC Jones”), a leading advisory firm headquartered in Rochester, New York, has joined the Atlantix Partners family of companies.
JC Jones joins six other leading accounting and IT services providers under the Atlantix Partners brand.
“We are enthusiastic about joining the Atlantix Partners family of companies,” said P.J.
“We couldn’t be more excited for our team and our clients to have JC Jones join our family of companies,” said Alexandra (Alex) Mores, Founder and CEO of Atlantix Partners.

Salons By JC Chooses Vagaro to Elevate Operational Efficiency for Thousands of Salon Professionals

Retrieved on:

Tuesday, January 16, 2024

Technology, Luxury, Professional Services, Specialty, Small Business, Fashion, Cosmetics, Retail, Software, Internet, Mobile, Wireless, Dream, Partnership, JC, Automation, Salon, Rest, Beauty salon

Vagaro, the leading salon and spa software for the hair and beauty industry, announced a partnership with Salons by JC, a leading salon suite franchisor in the U.S.

Key Points:

Vagaro, the leading salon and spa software for the hair and beauty industry, announced a partnership with Salons by JC, a leading salon suite franchisor in the U.S.
Through this collaboration, Vagaro will offer their salon software to modernize business operations and increase efficiency for more than 7,000 salon suite owners & renters across more than 150 SBJC locations.
“We have always prioritized the best interest of beauty professionals by providing flexible, affordable and scalable salon software to help them achieve their business goals.
Salons by JC President, Steve Griffey says, “We are thrilled to embark on this journey with Vagaro, they have long been the premier offering for salon software in the industry.

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Retrieved on:

Friday, December 22, 2023

DSMB, Immunodeficiency, BKV, BK virus, Sale, CMV, Data monitoring committee, MD, JC, ADV, EBV, Infection, BK, Investment, Cytomegalovirus, Human polyomavirus 2, Patient, Safety, JCV, Medical device

WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV). The company will discontinue its three global Phase 3 posoleucel studies – for prevention of clinically significant infections or diseases by multiple viruses, treatment of virus-associated hemorrhagic cystitis (vHC), and treatment of adenovirus (AdV) – following allogeneic hematopoietic cell transplant (allo-HCT). The company made the determination following three pre-planned analyses by three independent Data Safety Monitoring Boards (DSMBs) each of which recommended stopping its respective trial for futility after a review of the data suggested that each study was unlikely to meet its primary endpoint. There were no observed safety concerns raised by any of the DSMBs.

Key Points:

The company will discontinue its three global Phase 3 posoleucel studies – for prevention of clinically significant infections or diseases by multiple viruses, treatment of virus-associated hemorrhagic cystitis (vHC), and treatment of adenovirus (AdV) – following allogeneic hematopoietic cell transplant (allo-HCT).
AlloVir is in the process of notifying regulatory agencies and clinical trial investigators involved in these trials of the findings.
“In light of the DSMB recommendations, we will discontinue the prevention, vHC and AdV Phase 3 trials.
As of September 30, 2023, AlloVir had cash, cash equivalents and short-term investments of $213.3 million.

American Pacific Mining Reports up to 100 g/t Gold and 1,305 g/t Silver from 2023 Rock Chip Sampling at the Recently Expanded Tuscarora Project

Retrieved on:

Tuesday, December 12, 2023

Paragon, National instrument, QP, AG, CRD, Au, JC, Host, News, Danny Boy, Laboratory, Silver, APM, Project, ALS, ICP, AA, Soil

The Tuscarora District is located in Elko County on the east flanks of the 40-million-year-old Mt Blitzen caldera/volcanic complex.

Key Points:

The Tuscarora District is located in Elko County on the east flanks of the 40-million-year-old Mt Blitzen caldera/volcanic complex.
The nature of the mineralization is typical of this geologic setting and is comprised of high-level epithermal gold, gold/ silver, electrum and silver veins.
The district was discovered through placer mining in the late 1860s and underground mining began in 1870 with three mills being erected.
Two certified assay labs were used during the 2023 sampling campaign, Paragon and ALS Global.

ROTH MKM to Host 3rd Annual AgTech Answers Event on November 14th in New York City

Retrieved on:

Thursday, November 9, 2023

Taste, Gene editing, International finance, Agriculture, JC, Escape chair, CRISPR

Engage in a thoughtful dialogue on the rising significance of gene editing in agriculture, featuring experts from the forefront of advanced food production methods.

Key Points:

Engage in a thoughtful dialogue on the rising significance of gene editing in agriculture, featuring experts from the forefront of advanced food production methods.
Sector Specialist: Pam Marrone Ph.D., Co-Founder & Executive Chair of Invasive Species Corp. (PRIVATE)
1:30pm - A Technical Perspective on Global Markets with JC O’Hara - Managing Director, Chief Technical Strategist – ROTH MKM
The 1-on-1 portion of this event is for institutional clients of ROTH and is by invitation only.
For more information and how to registration, please see www.roth.com/conferences/upcoming-conferences , or contact your ROTH sales representative at (949) 720-5700 or e-mail: [email protected] .
This is not an offer or solicitation of the securities herein.

Medallion Announced Board Changes

Retrieved on:

Friday, October 27, 2023

MDL, JC

VANCOUVER, British Columbia, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medallion Resources Ltd. (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRDN) – “Medallion” or the “Company”) announced today that Rod McKeen and Andrew Morden have resigned from the Board of Directors, effective immediately.

Key Points:

VANCOUVER, British Columbia, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medallion Resources Ltd. (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRDN) – “Medallion” or the “Company”) announced today that Rod McKeen and Andrew Morden have resigned from the Board of Directors, effective immediately.
Mr. Cunningham currently serves as the President of VLP Inc., a renowned consulting firm specializing in navigating the intricacies of the public markets.
Gabriel Alonso, CEO, commented, “Both personally and on behalf of the Medallion Board, I thank Rod and Andrew for their tireless support of the Company over the past decade.
I welcome JC to the Board as we embark on a new phase of growth.”

johnnie-O Announces Appointment of John Collins as CEO

Retrieved on:

Wednesday, October 25, 2023

Fashion, Consumer, Retail, Footwear, Men, E-commerce, Collins, Life, Johnny O., Multimedia, Trust, Growth, Marketing, Retirement, Love, Celebrity board director, DTC, CMO, JC, Management

johnnie-O announced today that John Collins has joined the company as Chief Executive Officer and Board Member.

Key Points:

johnnie-O announced today that John Collins has joined the company as Chief Executive Officer and Board Member.
As CEO, John Collins succeeds Dave Gatto, who has played an instrumental role in johnnie-O's journey as CEO and Board Director since January 2015.
View the full release here: https://www.businesswire.com/news/home/20231025166302/en/
johnnie-O Announces Appointment of John Collins as CEO (Photo: Business Wire)
Collins began his distinguished career with Patagonia in 1996, where he spent over two decades championing brand storytelling that captivates consumers, creating quality products with clear consumer benefits, and developing robust omnichannel retail strategies.
johnnie-O Founder John O'Donnell expanded on this sentiment, saying, "John brings a wealth of experience and expertise in cultivating brands that consumers love and trust.